Am J Nucl Med Mol Imaging 2014;4(5):490-506
www.ajnmmi.us /ISSN:2160-8407/ajnmmi0000712
Review Article
Kinetic modeling in PET imaging of hypoxia
Fan Li1,2, Jesper T Joergensen1,2, Anders E Hansen1,3, Andreas Kjaer1,2
1
Cluster for Molecular Imaging, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark; 2Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Blegdamsvej 9,
2100 Copenhagen, Denmark; 3Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, DTU Nanotech, Technical University of Denmark, Building 423, 2800 Lyngby, Denmark
Received May 5, 2014; Accepted May 28, 2014; Epub September 6, 2014; Published September 15, 2014
Abstract: Tumor hypoxia is associated with increased therapeutic resistance leading to poor treatment outcome.
Therefore the ability to detect and quantify intratumoral oxygenation could play an important role in future individual
personalized treatment strategies. Positron Emission Tomography (PET) can be used for non-invasive mapping of
tissue oxygenation in vivo and several hypoxia speciic PET tracers have been developed. Evaluation of PET data
in the clinic is commonly based on visual assessment together with semiquantitative measurements e.g. standard
uptake value (SUV). However, dynamic PET contains additional valuable information on the temporal changes in
tracer distribution. Kinetic modeling can be used to extract relevant pharmacokinetic parameters of tracer behavior
in vivo that relects relevant physiological processes. In this paper, we review the potential contribution of kinetic
analysis for PET imaging of hypoxia.
Keywords: Cu-ATSM, 18F-FMISO, 18F-FETNIM, 18F-FAZA, oxygenation
Introduction
The majority of locally advanced solid tumors
exhibit hypoxic and even anoxic regions that
are heterogeneously distributed within the
tumor mass [1]. These regions are a result of an
imbalance between oxygen supply and consumption and can generally be divided into perfusion limited (acute) hypoxia, which is generated by the diffuse nature of tumor vasculature,
and diffusion limited (chronic) hypoxia, which
develops as the distance between tumor vasculature, and the expanding tumor cells
increases. Additionally, cancer associated anemia may contribute to the formation of tumor
hypoxia following a decrease in the bloods ability to carry the oxygen [2].
The intricate link between tumor hypoxia and
increased malignancy is well established [3-5].
In addition, hypoxic tumor cells represent an
important therapeutic problem because of
increased resistance towards ionizing radiation
and chemotherapy [6-9]. The therapeutic targeting of tumor hypoxia represents an attractive strategy for individualized therapy of can-
cer patients. In radiation oncology different
approaches such as the use of adjuvant hypoxia sensitizers (e.g. nimorazole) during radiation
therapy [10, 11]; therapeutic combinations aiming to increase tumor oxygenation [12-14]; and
modern high linear energy transfer radiation
strategies (e.g. heavy ion therapy) [15] has
been applied with varying results. Additionally,
heterogeneous delivery of radiation, also
termed dose painting, holds the potential to
selectively increase radiation dose to areas
with known therapeutic resistance, such as
hypoxic tumor regions. This approach is
extremely challenging, as it requires the ability
to continuously identify regional changes in
intratumoral oxygenation levels, and currently
knowledge is very limited with regard to how
regional oxygenation luctuates during therapy
[16, 17]. Therefore methods that allow for identiication of patients with hypoxic tumors that
would beneit from hypoxia-modiied treatment
could improve treatment eficacy. However,
presently no method has reached a position as
a clinically accepted routine approach for identiication of tumor hypoxia, even though a number of techniques have been evaluated to deter-
Kinetic modeling in hypoxia PET imaging
cal processes with high temporal and adequate spatial resolution.
At present the radiolabelled glucose analog, 2-deoxy-2-(18F)luoro-D-glucose (18FFDG) is the most used PET tracer in clinical
oncology. It utilizes that cancer cells take
up greatly elevated levels of glucose,
known as the Warburg effect [31, 32].
Additionally, 18F-FDG has also been proposed as a surrogate marker of tumor
hypoxia following the potential increased
cell metabolism from oxidative phosphorylation to glycolysis when oxygen level drops
[33]. This induce an increase in the uptake
of glucose but despite this well-characterized connection, preclinical and clinical
studies have reported conlicting results;
but in general 18F-FDG cannot be considFigure 1. Chemical structures of hypoxia speciic PET tracers.
18
ered as a consistent surrogate marker of
F-FMISO: 18F-luoromisonidazole; 18F-FETNIM: 18F-luoroerythronitroimidazole; 18F-FAZA: 18F-luoroazomycin; 64Cu-ATSM:
hypoxia in tumors [34-39]. Accordingly, sev64
Cu(II)diacethyl-bis(N4-methylthiosemicarbazone). Besides
eral radiotracers for speciic PET imaging of
64
Cu, Cu-ATSM can also be labeled with other radioactive cophypoxia including 18F-Fluoromisonidazole
per isotopes such as 60Cu, 61Cu and 62Cu.
18
F-FMISO, luoroazomycin (18F-FAZA), luoroerythronitroimidazole (18F-FETNIM) and
mine oxygenation in tissue. The polarographic
copper(II)diacethyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) have been developed
electrode is currently the only method that can
(Figure 1).
provide a direct measure of oxygen tension,
and it has been considered as the gold stanOne of the advantages of PET is the ability to
dard for measurement of tumor pO2 over the
measure radiotracer concentration in tissue or
last two decades [4, 18-20]. In addition, a diforgans. Semiquantitative approaches are often
ferent type of electrode based on the principle
used for analysis of PET images but the main
of oxygen-induced quenching of light emitted
drawback is that it does not take into account
by luorescent dye, has also been used for this
variations caused by underlying processes
purpose [21-23]. Immunohistochemical stainsuch as tracer delivery, trapping, competition
ing of exogenous or endogenous surrogate
with other molecules, and physical clearance
markers of hypoxia in tumor biopsies is another
[40]. Dynamic PET can be used to study tracer
approach often used to assess tumor oxygenpharmacokinetics and temporal changes in
ation [24-26]. However, these needle-based
uptake, and clinical studies have indicated that
methods have some limitations as they are
valuable additional information can be obtained
invasive procedures and only applicable for
from the proile of time activity curves (TACs)
tumors that are accessible with a needle.
[32, 41, 42]. Furthermore, mathematical modMoreover, these techniques only allows for the
eling based on non-invasive imaging data can
assessment of oxygenation in a limited volume
possibly be used to extract meaningful paramof the tumor microenvironment. The heterogeeters of tracer accumulation and distribution
neous distribution of hypoxic areas makes a
kinetics [40, 43-46].
non-invasive imaging approach attractive, and
different techniques such as magnetic resoBasically, tracer kinetic modeling is based on a
nance imaging (MRI) and electron paramagnetcompartmental model that is comprised of a
ic resonance (EPR) with oxygen sensitive
number of functional, homogenous units
probes have been applied for assessment of
termed compartments. These are interpreted
tumor oxygenation [27-30]. Additionally, posias separate, structureless pools of tracer in
tron emission tomography (PET) offers in vivo
distinct state. The tracer transport between
measurement and quantiication of physiologicompartments can be described by rate param-
491
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
Figure 2. Graphical representation of common 2-tissue compartment models. Model (A) is consisting of three components and each is a function of time expressed as time activity curves. Input function, Ca(t) consists primarily of
arterial blood and interstitial space close to vessels. The C1(t) compartment represents unbound tracer in tissue
whereas C2(t) compartment represents bound tracer. This model contains three kinetic parameters, k1-3. Model (B)
contains the same number of compartments but kinetic parameter also includes the transport rate constant k4.
Moreover, the netto inlux parameter, Ki can be calculated based on k1-3 in a irreversible model, and k1-4 can be used
to calculate the distribution volume, Vd in a reversible model.
eters, and usually the models are described
mathematically by irst order differential equations. Figure 2 demonstrates the two most
widely used model structures within tracer
kinetic studies. While a 2-tissue reversible
model is often applied in studies of neuroreceptor-ligands, a 2-tissue irreversible model
has been implemented in most studies of
hypoxia tracer kinetics [47, 48]. In principle,
additional compartments can be added to a
model in order to obtain a more realistic interpretation of tracer kinetic behavior in vivo,
including an increasing number of parameters.
However, increased complexity affects the
accuracy and reliability of the model parameter
estimation due to limitation of the nonlinear
minimization problem [49]. Therefore model
selection should be considered as a balance
between statistical accuracy and model complexity. As an alternative, graphical analysis is a
more computational eficient way to calculate
combinatorial parameters by turning a nonlinear problem into linear plots [50]. Thus the
slope of the linear part of Patlak and Logan
plots can be used to determine netto inlux
rate, Ki and distribution volume, Vd for tracers
with irreversible and reversible uptake, respectively.
492
Overall compartmental analysis provides a possibility to understand the tracer behavior in a
speciic tissue and allows for the derivation of
important kinetic parameters. This can provide
additional information on a metabolic processes at the molecular level and thereby potentially improve the diagnostic and prognostic potential of a PET tracer. This review focuses on
studies where compartment/kinetic modeling
has been applied on PET data for quantiication
of hypoxia.
18
F-FMISO
The majority of hypoxia PET tracers belongs to
a group of compounds termed nitroimidazoles
that have been used intensively as immunological markers for immunohistochemical procedures and lowcytometry [51-55]. Nitroimidazoles enter cells by diffusion and are reduced
by nitroreductases inversely correlated with
oxygen tension. In the presence of oxygen they
are able to leave the cell again, but under
hypoxic conditions the nitroimidazoles become
reduced and will be irreversibly trapped within
the cells [56, 57].
18
F-Fluoromisonidazole (18F-FMISO) was the
irst nitroimidazole-based radiotracers for
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
Figure 3. The model of 18F-FMISO transport and metabolism presented by Casciari et al. 18F-FMISO enters the target
tissue by lood low (F) and diffuse across the cell membrane, where it is reduced. KA is the rate constant describing
the rate by which FMISO is reduced. Cellular accumulation of FMISO and washout of diffusible product is running
side by side. Cc, Cp, Cbp, Cdp, Cdpe corresponds to 18F-FMISO concentration in tissue, in blood plasma, 18F-FMISO bound
product and cellular diffusible product, respectively. V T, η are the tissue speciic volume and dimensionless fractional variable. KA is related to the oxygen level and can be considered as a surrogate measure of hypoxia.
hypoxia PET imaging to be developed, and it
has been extensively used in both preclinical
and clinical studies [58-63].
The kinetic proile and characteristics of
18
F-FMISO has also been investigated in a number of studies applying various approaches. In
1995 Casciari et al. developed a mathematical
model based on knowledge on the cellular
metabolism and tracer transport in tissue. The
main objective was to quantify 18F-FMISO reaction rate constant, K A, a parameter related to
the level of cellular oxygen (see Figure 3).
Models performance was tested using Monte
Carlo simulation and itted to 18F-FMISO timeactivity PET data from human and rat tumors.
This demonstrated the importance of including
some transport limits such as parameter ixing
of the compartments representing tracer in the
tissue. In addition the effect of noise on accurately determination of K A was small when
some parameters were ixed at physiological
meaningful values; however, the accuracy of K A
was sensitive to the accuracy of the ixed
parameters [64].
Kelly and Brady also did a simulation work on
the spatiotemporal distribution of 18F-FMISO in
tumor microenvironment by applying a modular
approach to simulated data. They included
parameters to model spatial diffusion of free
493
18
F-FMISO and its reduced compounds and
modiied a conversional reversible 2-compartmental model, with a reaction-diffusion equation, in order to improve 18F-FMISO distribution
dynamics [65]. The model was then used to
generate simulated data based on patient plasma time activity curve as input. It was necessary to set transport parameter k4 = 0.
Additionally, a number of technical limitations
that inluenced the model were identiied. On
the basis on this, the kinetic and spatial effects
of diffusion could be disregarded in the data itting process. The adaptive model illustrated
that a reversible 2-compartment model with
varying diffusion distances and diffusion coeficients was able to generate more realistic
TACs. Moreover, it demonstrated that simulation models of tracer spatiotemporal distributions provides a options to investigate the
effects of heterogeneity on TACs and the relationships between image data and molecular
processes, prior to empirical studies.
Besides these simulation studies of 18F-FMISO,
a limited number of preclinical studies in mice
and rats have focused on kinetic modeling.
Whisenant et al. did a study in nude mice bearing Trastuzumab-resistant breast tumors in
order to test the reproducibility of kinetic
parameters derived from dynamic PET scan
protocols [66]. Mice received 60 min dynamic
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
PET scan six hours apart with 18F-FLT and
18
F-FMISO, respectively. They found that the
distribution volume, Vd and the net inlux constant, Ki were the most reproducible parameters for 18F-FMISO. In contrast transport constant k1 and trapping constant k3 were the most
variable. For 18F-FLT Vd, k3, and Ki were shown to
be the most reproducible parameters.
In another study Bejot et al. evaluated 18F-3NTR, a 3-nitro-1,2,4-triazole analogue (N(1)
substituted) (18F-3-NTR) against 18F-FMISO as
hypoxia PET tracer in tumor bearing mice and
concluded that 18F-3-NTR could not be considered a hypoxia imaging agent due to its poor
binding capacity [67]. Furthermore, based on
the Akaiki information criterion there was no
beneit of applying a 3-compartment irreversible model to describe 18F-FMISO kinetics when
compared to a 2-compartment irreversible
model.
In a recent study, Bartlett et al. investigated a
group of nude rats bearing prostate tumors in
order to ind a non-invasive approach based on
dynamic PET for better identiication of tumor
hypoxia [23]. Voxelwise kinetic parameters calculated from 2-compartment model itting to
18
F-FMISO uptake data were compared to pO2
measurements. When k1 and k2 were constrained, 18F-FMISO trapping rate, k3 was shown
to be a more robust discriminator for low pO2
within tumor tissue than a simple tissue-toplasma ratio. This suggest that voxelwise based
kinetic modeling could improve accuracy of
tumor hypoxia estimation.
Finally, the use of kinetic modeling of 18F-FMISO
has also been investigated in a few clinical
studies. Bruehlmeier et al. used 15O-H2O to
study the inluence of perfusion on the pharmacokinetics of 18F-FMISO in eleven patients with
brain cancer and observed an increased late
uptake in glioblastomas [68]. Pixel-wise comparison showed a positive relationship between
15
O-H2O and early uptake of 18F-FMISO, whereas no correlation was found for late 18F-FMISO
distribution. Standard 2- and 3-compartment
models and Logan graphical analysis were
used to calculate distribution volumes and
transport rate constants and found that a Vd
above one was indicative of active 18F-FMISO
uptake. Additionally, the 18F-FMISO uptake rate,
k1 was increased in all tumor tissue, compared
to values in white matter and in cortex. In
494
meningioma they found the highest value for k1
of all brain tumors. This increase k1 permitted
delineation of the meningioma in an early
18
F-FMISO PET image, but the tumor did not
exhibit subsequent 18F-FMISO accumulation
and was not visualized in the late PET images.
Accordingly, the 18F-FMISO distribution volume
in the meningioma was not increased despite a
high k1 value. However, despite Vd providing a
good measure of 18F-FMISO accumulation, it
was concluded that it does not offer additional
information compared to tumor-to-background
ratios of late PET images.
Using a similar experimental setup with 15O-H2O
and 18F-FMISO, Bruehlmeier et al. applied
graphical analysis on dynamic PET data from
six dogs with spontaneous sarcomas [69]. They
found that tumor tissue could be markedly
delineated from surrounding tissue including
muscles by positive inlux rate Ki derived from a
Patlak plot. The presence of tumor hypoxia was
conirmed by eppendorf electrode measurement.
In a study of head and neck cancer patients,
Thorwarth et al. performed quantitative image
analysis based on irreversible compartmental
modeling of dynamic 18F-FMISO PET data [70].
This model was different from previous
approaches by including weighing factors for
the respective model compartments. The input
function was determined from the signal of a
reference tissue and the irreversible model was
applied to identify and quantify TACs using a
voxel-to-voxel approach. Evaluation of model
performance indicated that the parameters
derived from the kinetic model were superior to
SUV for quantiication in extremely low oxygenated and necrotic tissue areas. In another study
the same model was applied to a small group of
head and neck cancer patients that were
scanned dynamically for 60 min prior to radiotherapy [42]. Assessment parameters representing hypoxia and perfusion derived from the
kinetic model were not able to predict treatment outcome. However, Thorwarth et al. introduced a novel parameter, termed the malignancy value, that was dependent on both hypoxia
and perfusion characteristics of the tissue.
This malignancy value could be used as a prognostic factor indicating that the parameters
may provide additive information. Furthermore,
in a preclinical study, Cho et al. adapted
Thorwarth’s model for comparing perfusion
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
and hypoxia parameters derived from MRI with
18
F-FMISO PET in a rat prostate cancer model
[71]. The tumor perfusion derived from DCEMRI was found positively correlated with early
18
F-FMISO PET but inversely correlated to late
slope maps of the 18F-FMISO PET time-activity
curve.
Wang et al. applied a generic irreversible 2-compartmental model to analyze dynamic 18FFMISO PET dataset within three regions of an
image phantom [72]. The purpose of the phantom study was to determine the statistical
accuracy and precision of the kinetic analysis.
The results from the phantom study was used
for guidance in a clinical dynamic 18F-FMISO
PET study of nine head and neck cancer
patients with local squamous cell carcinoma
[73]. Based on this they identiied Ki as a potential hypoxia marker and found a signiicant correlation to 18F-FMISO tumor-to-blood ratio.
In addition to modeling of tumor hypoxia,
18
F-FMISO has also been used in studies of
ischemic stroke. Takasawa et al. performed a
rat stoke study that included dynamic PET with
18
F-FMISO. In order to obtain quantitative comparison between the tracer retention from
affected and unaffected cerebral hemispheres,
an irreversible compartmental model was used
for calculation of k1 and Ki [74]. Immediately
after the occlusion of the middle cerebral artery
a remarkable increased Ki was observed in the
affected site. This suggests that 18F-FMISO can
potentially be used to visualize the occlusion at
a very early stage. However, in spite of histological indings, no difference in either k1 and Ki
was found between affected and unaffected
cerebral hemispheres 48 hours after the occlusion. In another study Hong et al. used the dataset generated by Takasawa et al. to perform
kinetic analysis [75]. Basis functions from plasma input compartment (BAFPIC) model is a
modiied version of the standard compartment
model approach and can be applied to both
reversible and irreversible models. In this study
BAFPIC was compared to both conventional
compartment modeling, as well as the most
common analysis methods for generation of
parametric maps. The BAFPIC method showed
lower variability and bias than nonlinear least
squares modeling in hypoxic tissue. In addition,
voxel based parametric mapping of dynamic
imaging was shown to be less affected by
noise-induced variability compared to nonlin-
495
ear least squares modeling and Patlak graphical analysis. BAFPIC could therefore potentially
be applied to other tracers with irreversible
characteristics, and although the focus of this
study was on voxelwise modeling, other kinetic
parameter estimations in regions with noise
can be performed using the BAFPIC algorithm
as well.
18
F-FETNIM
Even though 18F-FMISO has been used extensively, a slow hypoxia speciic retention and
clearance from non-hypoxic tissue is a limitation and results in low tumor-to-background
contrast [76]. To improve image quality
18
F-labeled nitroimidazole analogs including
18
F-FETNIM, 2-nitroimidazole nucleoside analog (18F-HX4) and 2-(2-Nitromidazole-1H-yl)-N(2,2,3,3,3-pentaluoropropyl)acetamind (18FEF5), that have structural modiications - with
changed lipophilic properties, have been developed to overcome the basic pharmacokinetic
limitations [44, 77, 78]. 18F-FETNIM was introduced as a novel hypoxia-speciic PET tracer in
1995 and has shown promising results in clinical studies [77, 79].
In studies in patients with head and neck cancer Lehtiö et al. performed compartmental
analysis based on dynamic 18F-FETNIM PET
scans [80, 81]. They adapted the model previously introduced by Casciari et al. for 18F-FMISO
metabolism and transport (Figure 3). Blood
low rate (F), tissue activity correction factors
(β1, β2) and cellular 18F-FETNIM reaction rate
(K A), considered the hypoxia speciic binding
rate, were estimated by itting the model to
dynamic PET data. They found that the level of
tracer uptake (K A) was most sensitive to changes in oxygen in tissue with high blood low.
Furthermore, distribution volumes derived from
Logan plots correlated positively with the
tumor-to-plasma ratio but not with tumor-tomuscle ratio. This suggests that plasma should
be preferred as reference tissue rather than
muscle.
18
F-FAZA
Like 18F-FETNIM, 18F-FAZA is a next generation
nitroimidazole-based PET tracer. Several studies have compared the tracer kinetics of
18
F-FAZA with 18F-FMISO and reported of
improvements in washout from non-hypoxic tis-
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
sue and faster renal clearance [82-84].
Moreover, a recent study of 50 patients conirmed the feasibility of using FAZA PET for
detection of tumor hypoxia in clinic [85].
A few studies have focused on kinetic modeling
of dynamic 18F-FAZA PET. Reischl et al. demonstrated an increased tumor to blood ratio due
to faster vascular clearance of 18F-FAZA when
compared to 18F-FMISO and that is one of most
important criteria for hypoxia tracer development in relation to hypoxia imaging optimization [86].
Busk et al. reported a dynamic 18F-FAZA animal
study in three tumor xenograft models of squamous cell carcinomas of the cervix. The dynamic data were analyzed by an irreversible 2-compartmental model. Overall variations in the
pattern of TACs were tumor type dependent.
The inlux rate constant Ki was shown to have a
strong correlation to late 18F-FAZA uptake in
two of three tumors models. On the other hand,
weak correlation between irreversible parameter k3 and late 18F-FAZA uptake was observed in
two of three tumor models [87].
Two small clinical studies have used dynamic
18
F-FAZA PET data to compare different kinetic
models. While Shi et al. used a voxelvise
approach to correlate model parameters of
interest with perfusion measured by 15O-H2O
PET in patients with head and neck cancer;
Verwer et al. applied the Akaiki information criterion to evaluate model itting to TACs obtained
from nine non-small cell lung cancer patients
[88, 89]. Both studies concluded that a reversible 2-compartment model showed the best
correlation and robustness with their expectations and assumptions.
Cu-ATSM
Beside the nitromidazole-based compounds, a
copper labeled metallocomplex termed copper(II)diacethyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) has been applied as radiotracer for PET imaging of tumor hypoxia [90]. Image
quality is generally superior to the nitroimidazoles, however, despite promising clinical performance [91-93], preclinical data from experimental hypoxia imaging is conlicting with
regard to tracer selectivity [94-97]. The mechanism of tracer uptake and retention is still not
fully understood but it is believed that Cu(II)-
496
ATSM is reduced to the unstable [Cu(I)- ATSM]complex in both hypoxic and normoxic cells.
Under normoxic conditions [Cu(I)-ATSM]- is
reoxidized and thereby able to of leave the cell.
The reoxidation of [Cu(I)-ATSM]- is, however, not
expected to occur under hypoxic conditions,
and the electrochemically negative molecule
becomes irreversibly trapped and dissociates
[98, 99].
As for the other hypoxia PET tracers there are
only limited data concerning the pharmacokinetics of Cu-ATSM. A simulation work carried
out by Holland et al. applied a model based on
an in vitro study on cellular uptake and retention of 64Cu-ATSM in EMT6 murine carcinoma
cells. The model demonstrated that a decrease
in cellular pH may protonate the unstable Cu(I)ATSM complex and increase the rate of dissociation [100]. The kinetic analysis was consistent with experimental cellular uptake.
Bowen et al. suggested an electrochemical
models based on the retention mechanisms for
18
F-FMISO and 61Cu-ATSM, respectively [101].
In this work the preclinical data were compared
to transformation functions derived from tracer
uptake and pO2 measurements. Comparisons
between 61Cu-ATSM and 18F-FMISO uptake
showed inconsistent results, but this could be
due to the different retention mechanisms.
However, the results suggested that 18F-FMISO
uptake was superior for differentiation of a
wide range of pO2 values, but 61Cu-ATSM uptake
provided more reliable information on variations at low pO2 range.
In another study Dalah et al. performed a simulation work based on the model adapted from
Kelly and Brady [102]. This reined model was
used to simulate realistic TACs that were comparable to 64Cu-ATSM patient TACs and showed
favorable tumor delineation in form of higher
tumor to blood ratio compared to 18F-FMISO.
Kinetic modeling of Cu-ATSM PET has also
been applied in a few animal studies. Lewis et
al. evaluated Cu-ATSM retention in canine models of hypoxic myocardium [97]. Monoexponential analysis and 2-compartmental model
itting were applied to the TACs in order to
determinate washout of Cu-ATSM from regions
of the myocardium. Based on the assumption
that the relationship between washout and
retention is inverse proportional, they reported
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
of an increase of Cu-ATSM retention in ischemic regions when compared to normal myocardium. Moreover, the data also indicated that
Cu-ATSM retention in hypoxic regions of the
myocardium was independent of increased
perfusion and that there was no retention in
necrotic tissue.
Recently, McCall et al. performed a preclinical
study of 64Cu-ATSM uptake in rats bearing FaDu
human head and neck cancer xenografts.
Graphical analyses were used to derive the net
inlux parameter, Ki and distribution volume, Vd.
In general, a stronger linear relationship was
found for Logan plots but both parameters
were signiicantly higher in tumor tissue when
compared to muscle tissue. Additionally, a continuous increasing tumor-to-muscle ratio was
observed [103].
Finally, Cu-ATSM has been used in multitracer
PET studies where two or three tracers were
administered with delayed injections. Following
image separation, signal recovery was performed based on differences in tracer kinetics
and physical decay. In a phantom study of
62
Cu-ATSM and the perfusion PET tracer,
62
Copper-pyruvaldehyde-bis[N4-methylthiosemicarbazone] (62Cu-PTSM), Rust et al. demonstrated a great similarity between perfusion
and hypoxia parameters obtained by the dual
tracer approach, and parameters estimated by
single-tracer imaging [104]. The results were
later conirmed by Black et al. that adapted the
phantom study protocol and used it for
62
Cu-ATSM and 62Cu-PTSM PET imaging in dogs
with spontaneous tumors [105]. Rate constants obtained from irreversible 2-compartment modeling was used to evaluate the signal
separation of the two PET tracers. However,
while k1 and k2 could be recovered from the
mixed PET signal the recovery of k3 was more
problematic. The same group has also experimented with a triple-tracers setup including
18
F-FDG [106]. Altogether, the multitracer
approach can potential provide different functional information about physiological processes within a short period of time; thereby
decreasing the possible effect of microenvironmental changes. However, there are some
questions there needs to be address with
regard to the long dynamic acquisition time,
and the risk of losing information as a consequence of temporal overlap.
497
Table 1 summaries studies on kinetic modeling
of hypoxia using PET tracers.
Challenges in kinetic modeling of hypoxia PET
tracers
Studies on kinetic modeling of hypoxia PET
tracer needs also deal with the issues, related
to acquisition of dynamic PET data in general.
The amplitude of noise can be inluenced by
several physical factors such as the radiopharmaceutical properties of the tracer, injected
dose, frame duration, and the sensitivity of the
PET camera. In addition, the size of the volumes of interest (VOI) or voxels will also have
effect on the scale of noise. In quantitative
analysis of dynamic PET data, the accuracy of
kinetic parameter estimation is not only related
to the signal to noise ratio, but also the number
of model parameters and selection of estimation method [107].
Non-linear least square optimization is the
most widely used technique to perform curveitting for parameter estimation in conventional
compartment modeling [8, 25, 26]. The accuracy of both curve-itting and determination of
particular parameters is sensitive to selection
of initial conditions [108]. If the initial conditions are improper, it becomes problematic to
ind a global minimum of the residual sum of
squares for parameters in a multidimensional
itting space [49, 109, 110]. A rational way to
obtain initial conditions is by applying parameter estimates from similar tracer kinetic studies. Likewise, species and organ dependent
physiological measurements found in literature
can be used to deine the range for parameter
boundaries. If no initial conditions are available
simulation or phantom studies can be used to
determine approximate values that can be
used for model optimization. In addition, a
number of linearizing methods can be applied
to reduce computational time at the cost of limited model parameter as output [50]. Basis
function and generalized linear least squares
method are other options that reduce the processing time of parameter estimation compared to nonlinear least-squares approach [59,
111].
The input function has great impact on the
model performance, and robust determination
is crucial for the accuracy of parameter calculation [112, 113]. The input function is deined as
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
Table 1. Overview of kinetic modeling work with regard to hypoxia using different hypoxia PET tracers
Tracer
Image Targeting
Methods
Application
Species
Authors
18
F-FMISO
Hypoxia
Voxelwise kinetic modeling
Oncology/Prostate tumor
Rat
Bartlett et al. [23]
F-FMISO
-
Oncology
Rat
Casciari et al. [64]
Noninvasive pO2 measurement
18
3
H-FMISO
18
15
F-FMISO
Kinetic model
Monte Carlo simulations
Hypoxia, perfusion
O-H2O
Dynamic PET
Patient
Oncology/Brain tumor
Patient
Bruehlmeier et al. [68]
Bruehlmeier et al. [69]
Kinetic models
Logan graphical analysis
18
15
F-FMISO
Hypoxia, perfusion
Patlak graphical analysis
Oncology/Spontaneous sarcomas
Dog
Hypoxia
Modular simulation
Oncology/Model evaluation
Simulation work Kelly and Brady et al.
[65]
O-H2O
18
F-FMISO
Probability density function
18
18
F-FMISO
Hypoxia
Kinetic model
Oncology/Model evaluation
Phantom study
Wang et al. [72]
F-FMISO
Hypoxia
Pharmacokinetic analysis
Oncology/Head and neck cancer
Patient
Wang et al. [73]
Oncology/Head and neck cancer
Patient
Thorwarth et al. [70]
Oncology/Radiotherapy
Patient
Thorwarth et al. [42]
Oncology/Prostate tumor
Rat
Cho et al. [71]
Oncology/Non-immunogenic carcinoma
Mouse
Bejot et al. [67]
Scan protocol validation
Mouse
Whisenant et al. [66]
Dynamic PET/CT
18
F-FMISO
Hypoxia, perfusion
Dynamic PET
Two compartment model
18
F-FMISO
Hypoxia
Dynamic PET
Two compartment model
18
F-FMISO
Hypoxia
DCE-MRI
Dynamic PET
Autoradiography
18
F-FMISO
18
F-3-NTR
18
F-FMISO
18
Hypoxia
Dynamic PET
Graphical analysis
F-FDG
18
Dynamic PET
Compartment modeling
F-FDG
18
18
Hypoxia
Graphical analysis
F-FMISO
Stroke
Dynamic PET
Stroke
Rat
Takasawa et al. [74]
F-FMISO
Hypoxia
Dynamic PET
Stroke
Rat
Hong et al. [75]
Oncology/Head and neck cancer
Patient
Lehtio et al. [80]
Oncology/Head and neck cancer
Patient
Lehtio et al. [81]
Voxelwise Kinetic analysis based on basis
function method
18
F-FETMIN Hypoxia
Dynamic PET
Tumor to plasma ratio
Tumor to plasma ratio
18
F-FETMIN Hypoxia
Dynamic PET
Compartment analysis
498
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
18
F-FAZA
Hypoxia
Dynamic PET
Oncology/Squamous cell carcinoma
Mouse
Busk et al. [87]
Oncology/Head and neck cancer
Patient
Shi et al. [88]
Immunohistochemical staining
Immunohistochemical staining
18
15
F-FAZA
Hypoxia, perfusion
O-H2O
18
F-FAZA
60
Cu-ATSM
Dynamic PET
Kinetic model
Hypoxia
Dynamic PET/CT
Oncology/No-small cell lung cancer
Patient
Verwer et al. [89]
Hypoxia
Compartment analysis
Myocardial ischemia
Dog
Lewis et al. [97]
64
Cu-ATSM
64
Cu-ATSM
64
Cu-ATSM
Hypoxia
Non-steady-state kinetic simulations
Oncology/EMT6 murine carcinoma
Mouse
Holland et al. [100]
Cu-ATSM
Hypoxia
Electrochemical model
Oncology/Head and neck cancer
Patient
Bowen et al. [101]
61
18
F-FMISO
Transformation function
pO2 microelectrode
64
Cu-ATSM
Hypoxia
Kinetic modeling
Oncology/Radiotherapy
Simulation work Dalah et al. [102]
64
Cu-ATSM
Hypoxia
Dynamic PET
Oncology/Head and neck squamous cell
carcinoma
Rat
Multiple tracer protocol
Simulation work Rust et al. [104]
Dynamic PET
Multiple tracer protocol
Dog
Black et al. [105]
Compartment analysis
Signal separation and recovery
Dynamic PET
Multiple tracer protocol
Dog
Black et al. [106]
Compartment analysis
Signal separation and recovery
Autoradiography
McCall et al. [103]
Immunohistochemical staining
62
Cu-PTSM
62
Cu-ATSM
62
Cu-PTSM
62
Cu-ATSM
18
F-FDG
62
Cu-PTSM
62
Cu-ATSM
499
Hypoxia, perfusion
Dynamic PET
62
Hypoxia, perfusion
Hypoxia, perfusion and glycolysis
Cu-ATSM
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
blood time active concentration and can be
obtained either by blood sampling or noninvasively from the left ventricle or large vessels by
an image derived approach [89, 113, 114].
When using arterial blood sampling the input
function should be corrected for dispersion and
delay. On the other hand, for the non-invasive
method a number of artifacts such as partial
volume effect and respiratory movements can
lead to misinterpretation [115]. Additionally,
correction for plasma binding and metabolites
should be considered.
Besides the technical aspects of kinetic modeling of dynamic PET data there are also factors
more speciic related to hypoxia imaging that
needs to be considered. The hypoxia tracers
that have been applied in dynamic PET imaging
are lipophilic compounds that enter cells by
free diffusion, become metabolized and consequently trapped within the cell. Based on the
proposed trapping mechanisms of used hypoxia-speciic tracers it is therefore reasonable to
assume that they will be unable to leave the
cell for the duration of the PET acquisition. On
this basis, an irreversible model will be most
suitable to relect tracer accumulation in vivo.
However, in studies comparing different compartment models for FAZA PET the difference
between reversible and irreversible two compartment models were negligible [88, 89].
Importantly, recent studies have suggested
that Cu-ATSM accumulation can perhaps be
inluenced by copper metabolism and that
there can also be an eflux of Cu-ATSM or the
radioactive copper from cells [116, 117], which
should be kept in mind when applying kinetic
models to dynamic Cu-ATSM PET data.
The majority of studies on kinetic modeling of
hypoxia PET tracers are focused on cancer. As
previously mentioned perfusion limited (acute)
hypoxia is caused by changes in local tumor
blood low, and regional oxygenation can therefore suddenly change. These luctuations represent a challenge, as the estimated parameters
could be average values of varying oxygenation
during the dynamic PET acquisition. In order to
implement the use of kinetic models in clinic,
the reproducibility of model output is an important part of the validation process. The reproducibility of model parameters derived from
dynamic 18F-FMISO PET has been investigated
and some degree of variations was observed
[66]. However, part of this variation could be
500
due to the luctuating nature of acute hypoxia
that inluence tracer uptake and potentially
also impact model parameters. Moreover,
because hypoxia is a heterogeneous phenomenon with microregional differences in oxygen
tension within a target tissue. This represents a
challenge for quantiication of PET imaging as
uptake in a VOI will represent an average value
with contribution from multiple microregions.
This will also be relected in the parameters
estimated based on TACs generated from these
VOIs. As an alternative, voxel-based tracer
kinetic modeling can be applied and more precisely relects the tracer behavior in smaller
subvolumes [70, 118]. However, computation
time for this approach is demanding, and the
error scale will be much higher, compared to
parameters calculated based on TACs derived
from larger VOIs. Therefore it is important to get
a reasonable balance between the signal to
noise ratio and the deinition of voxel size and
frame duration. Increasing the injected dose
can be a way to improve the signal to noise
ratio but this will also increase the absorbed
dose and should therefore be considered with
caution.
Conclusion and future perspectives
Dynamic PET based kinetic modeling represents a methodology that can potentially be
used to extract additional information of cellular processes. Despite some promising results,
a number of technical dificulties and limitations need to be solved for clinical implementation, e.g. the limited ield of view in clinical PET
scanners, and development of methods for
robust determination of the input function without continuous blood sampling. Several studies
have shown that it is possible to obtain kinetic
parameters from dynamic hypoxia PET data but
at present validation of model output against
other modalities is sparse. This review points
out the potential applications of dynamic hypoxia PET imaging but before a kinetic model can
be fully integrated in the clinic it needs to be
validated and shown that it contributes to the
current assessment routine.
Disclosure of conlict of interest
None.
Address correspondence to: Fan Li, Cluster for
Molecular Imaging, Faculty of Health Sciences,
University of Copenhagen, Blegdamsvej 3B, 2200
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
Copenhagen N, Denmark. Tel: +45 35326007; Fax:
+45 35327248; E-mail: fanli@sund.ku.dk
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
501
Hockel M and Vaupel P. Tumor hypoxia: deinitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266276.
Vaupel P and Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and
cellular response. Oncologist 2004; 9 Suppl 5:
4-9.
Hockel M, Schlenger K, Mitze M, Schaffer U
and Vaupel P. Hypoxia and Radiation Response
in Human Tumors. Semin Radiat Oncol 1996;
6: 3-9.
Brizel DM, Sibley GS, Prosnitz LR, Scher RL and
Dewhirst MW. Tumor hypoxia adversely affects
the prognosis of carcinoma of the head and
neck. Int J Radiat Oncol Biol Phys 1997; 38:
285-289.
Nordsmark M, Hoyer M, Keller J, Nielsen OS,
Jensen OM and Overgaard J. The relationship
between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1996; 35: 701-708.
Gray LH, Conger AD, Ebert M, Hornsey S and
Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a
factor in radiotherapy. Br J Radiol 1953; 26:
638-648.
Brizel DM, Dodge RK, Clough RW and Dewhirst
MW. Oxygenation of head and neck cancer:
changes during radiotherapy and impact on
treatment outcome. Radiother Oncol 1999;
53: 113-117.
Huang SC, Williams BA, Krivokapich J, Araujo
L, Phelps ME and Schelbert HR. Rabbit myocardial 82Rb kinetics and a compartmental
model for blood low estimation. Am J Physiol
1989; 256: H1156-1164.
Tredan O, Galmarini CM, Patel K and Tannock
IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:
1441-1454.
Skov KA and MacPhail S. Low concentrations
of nitroimidazoles: effective radiosensitizers at
low doses. Int J Radiat Oncol Biol Phys 1994;
29: 87-93.
Lee DJ, Moini M, Giuliano J and Westra WH.
Hypoxic sensitizer and cytotoxin for head and
neck cancer. Ann Acad Med Singapore 1996;
25: 397-404.
Kaanders JH, Bussink J and van der Kogel AJ.
ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-737.
Jonathan RA, Wijffels KI, Peeters W, de Wilde
PC, Marres HA, Merkx MA, Oosterwijk E, van
der Kogel AJ and Kaanders JH. The prognostic
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
value of endogenous hypoxia-related markers
for head and neck squamous cell carcinomas
treated with ARCON. Radiother Oncol 2006;
79: 288-297.
Bernier J, Denekamp J, Rojas A, Trovo M, Horiot
JC, Hamers H, Antognoni P, Dahl O, Richaud P,
Kaanders J, van Glabbeke M and Pierart M.
ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung
cancer: a phase I/II study by the EORTC. Radiother Oncol 1999; 52: 149-156.
Loefler JS and Durante M. Charged particle
therapy--optimization, challenges and future
directions. Nat Rev Clin Oncol 2013; 10: 411424.
Brurberg KG, Thuen M, Ruud EB and Rofstad
EK. Fluctuations in pO2 in irradiated human
melanoma xenografts. Radiat Res 2006; 165:
16-25.
Brurberg KG, Skogmo HK, Graff BA, Olsen DR
and Rofstad EK. Fluctuations in pO2 in poorly
and well-oxygenated spontaneous canine tumors before and during fractionated radiation
therapy. Radiother Oncol 2005; 77: 220-226.
Vaupel P, Schlenger K, Knoop C and Hockel M.
Oxygenation of human tumors: evaluation of
tissue oxygen distribution in breast cancers by
computerized O2 tension measurements. Cancer Res 1991; 51: 3316-3322.
Brizel DM, Scully SP, Harrelson JM, Layield LJ,
Bean JM, Prosnitz LR and Dewhirst MW. Tumor
oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943.
Nordsmark M, Bentzen SM, Rudat V, Brizel D,
Lartigau E, Stadler P, Becker A, Adam M, Molls
M, Dunst J, Terris DJ and Overgaard J. Prognostic value of tumor oxygenation in 397 head and
neck tumors after primary radiation therapy.
An international multi-center study. Radiother
Oncol 2005; 77: 18-24.
Grifiths JR and Robinson SP. The OxyLite: a ibre-optic oxygen sensor. Br J Radiol 1999; 72:
627-630.
Tran LB, Bol A, Labar D, Jordan B, Magat J, Mignion L, Gregoire V and Gallez B. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry
and 19F-MRI relaxometry. Radiother Oncol
2012; 105: 29-35.
Bartlett RM, Beattie BJ, Naryanan M, Georgi
JC, Chen Q, Carlin SD, Roble G, Zanzonico PB,
Gonen M, O’Donoghue J, Fischer A and Humm
JL. Image-guided PO2 probe measurements
correlated with parametric images derived
from 18F-luoromisonidazole small-animal PET
data in rats. J Nucl Med 2012; 53: 1608-1615.
Kizaka-Kondoh S and Konse-Nagasawa H. Signiicance of nitroimidazole compounds and
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
502
hypoxia-inducible factor-1 for imaging tumor
hypoxia. Cancer Sci 2009; 100: 1366-1373.
Muzic RF Jr and Christian BT. Evaluation of objective functions for estimation of kinetic parameters. Med Phys 2006; 33: 342-353.
Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang
SC and Schelbert HR. Noninvasive quantiication of myocardial blood low in humans. A direct comparison of the [13N]ammonia and the
[15O]water techniques. Circulation 1996; 93:
2000-2006.
Rijpkema M, Schuuring J, Bernsen PL, Bernsen
HJ, Kaanders JH, van der Kogel AJ and Heerschap A. BOLD MRI response to hypercapnic hyperoxia in patients with meningiomas: correlation with Gadolinium-DTPA uptake rate. Magn
Reson Imaging 2004; 22: 761-767.
Remmele S, Dahnke H, Flacke S, Soehle M,
Wenningmann I, Kovacs A, Traber F, Muller A,
Willinek WA, Konig R, Clusmann H, Gieseke J,
Schild HH and Murtz P. Quantiication of the
magnetic resonance signal response to dynamic (C)O(2)-enhanced imaging in the brain
at 3 T: R*(2) BOLD vs. balanced SSFP. J Magn
Reson Imaging 2010; 31: 1300-1310.
Yasui H, Matsumoto S, Devasahayam N, Munasinghe JP, Choudhuri R, Saito K, Subramanian S, Mitchell JB and Krishna MC. Low-ield
magnetic resonance imaging to visualize
chronic and cycling hypoxia in tumor-bearing
mice. Cancer Res 2010; 70: 6427-6436.
Bobko AA, Dhimitruka I, Eubank TD, Marsh CB,
Zweier JL and Khramtsov VV. Trityl-based EPR
probe with enhanced sensitivity to oxygen.
Free Radic Biol Med 2009; 47: 654-658.
Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps
M, Ido T, Casella V, Fowler J, Gallagher B, Hoffman E, Alavi A and Sokoloff L. Measurement of
local cerebral glucose metabolism in man with
18F-2-luoro-2-deoxy-d-glucose. Acta Neurol
Scand Suppl 1977; 64: 190-191.
Bomanji JB, Costa DC and Ell PJ. Clinical role of
positron emission tomography in oncology.
Lancet Oncol 2001; 2: 157-164.
Wang GL, Jiang BH, Rue EA and Semenza GL.
Hypoxia-inducible factor 1 is a basic-helix-loophelix-PAS heterodimer regulated by cellular O2
tension. Proc Natl Acad Sci U S A 1995; 92:
5510-5514.
Zimny M, Gagel B, DiMartino E, Hamacher K,
Coenen HH, Westhofen M, Eble M, Buell U and
Reinartz P. FDG--a marker of tumour hypoxia?
A comparison with [18F]luoromisonidazole
and pO2-polarography in metastatic head and
neck cancer. Eur J Nucl Med Mol Imaging
2006; 33: 1426-1431.
Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder
TH, O’Keefe GJ and Scott AM. Lack of correla-
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
tion of hypoxic cell fraction and angiogenesis
with glucose metabolic rate in non-small cell
lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006; 47:
1921-1926.
Dierckx RA and Van de Wiele C. FDG uptake, a
surrogate of tumour hypoxia? Eur J Nucl Med
Mol Imaging 2008; 35: 1544-1549.
Gagel B, Reinartz P, Dimartino E, Zimny M,
Pinkawa M, Maneschi P, Stanzel S, Hamacher
K, Coenen HH, Westhofen M, Bull U and Eble
MJ. pO(2) Polarography versus positron emission tomography ([(18)F] luoromisonidazole,
[(18)F]-2-luoro-2’-deoxyglucose). An appraisal
of radiotherapeutically relevant hypoxia.
Strahlenther Onkol 2004; 180: 616-622.
Bentzen L, Keiding S, Horsman MR, Falborg L,
Hansen SB and Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-luorinated tracers and positron emission tomography--a study evaluating
[18F]Fluoro-2-deoxy-D-glucose. Acta Oncol
2000; 39: 629-637.
Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC and Humm JL. Dependence of
FDG uptake on tumor microenvironment. Int J
Radiat Oncol Biol Phys 2005; 62: 545-553.
Willemsen AT and van den Hoff J. Fundamentals of quantitative PET data analysis. Curr
Pharm Des 2002; 8: 1513-1526.
Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ and
Bares R. Prognostic impact of hypoxia imaging
with 18F-misonidazole PET in non-small cell
lung cancer and head and neck cancer before
radiotherapy. J Nucl Med 2005; 46: 253-260.
Thorwarth D, Eschmann SM, Scheiderbauer J,
Paulsen F and Alber M. Kinetic analysis of dynamic 18F-luoromisonidazole PET correlates
with radiation treatment outcome in head-andneck cancer. BMC Cancer 2005; 5: 152.
Gunn RN, Gunn SR, Turkheimer FE, Aston JA
and Cunningham VJ. Positron emission tomography compartmental models: a basis pursuit
strategy for kinetic modeling. J Cereb Blood
Flow Metab 2002; 22: 1425-1439.
Dolbier WR Jr, Li AR, Koch CJ, Shiue CY and
Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a
new luorination procedure. Appl Radiat Isot
2001; 54: 73-80.
Rijpkema M, Kaanders JH, Joosten FB, van der
Kogel AJ and Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent
uptake in human tumors. J Magn Reson Imaging 2001; 14: 457-463.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr
NA, Parker GJ, Port RE, Taylor J and Weisskoff
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
503
RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI
of a diffusable tracer: standardized quantities
and symbols. J Magn Reson Imaging 1999; 10:
223-232.
Phelps M. PET: Molecular Imaging and Its Biological Applications. New York: Springer; 2004.
Takesh M. The Potential Beneit by Application
of Kinetic Analysis of PET in the Clinical Oncology. ISRN Oncol 2012; 2012: 349351.
Kadrmas DJ and Oktay MB. Generalized separable parameter space techniques for itting
1K-5K serial compartment models. Med Phys
2013; 40: 072502.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey
SL, Schlyer DJ, MacGregor RR, Hitzemann R,
Bendriem B, Gatley SJ, et al. Graphical analysis of reversible radioligand binding from timeactivity measurements applied to [N-11Cmethyl]-(-)-cocaine PET studies in human
subjects. J Cereb Blood Flow Metab 1990; 10:
740-747.
Kaanders JH, Wijffels KI, Marres HA, Ljungkvist
AS, Pop LA, van den Hoogen FJ, de Wilde PC,
Bussink J, Raleigh JA and van der Kogel AJ. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck
cancer. Cancer Res 2002; 62: 7066-7074.
Olive PL, Durand RE, Raleigh JA, Luo C and
Aquino-Parsons C. Comparison between the
comet assay and pimonidazole binding for
measuring tumour hypoxia. Br J Cancer 2000;
83: 1525-1531.
Raleigh JA, Chou SC, Arteel GE and Horsman
MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat
Res 1999; 151: 580-589.
Chang Q, Jurisica I, Do T and Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human
pancreatic cancer. Cancer Res 2011; 71:
3110-3120.
Andreyev A and Celler A. Dual-isotope PET using positron-gamma emitters. Phys Med Biol
2011; 56: 4539-4556.
Chapman JD, Baer K and Lee J. Characteristics
of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer
Res 1983; 43: 1523-1528.
Chapman JD, Franko AJ and Sharplin J. A marker for hypoxic cells in tumours with potential
clinical applicability. Br J Cancer 1981; 43:
546-550.
Rasey JS, Koh WJ, Grierson JR, Grunbaum Z
and Krohn KA. Radiolabelled luoromisonidazole as an imaging agent for tumor hypoxia. Int
J Radiat Oncol Biol Phys 1989; 17: 985-991.
[59] Boellaard R, Knaapen P, Rijbroek A, Luurtsema
GJ and Lammertsma AA. Evaluation of basis
function and linear least squares methods for
generating parametric blood low images using
15O-water and Positron Emission Tomography.
Mol Imaging Biol 2005; 7: 273-285.
[60] Valk PE, Mathis CA, Prados MD, Gilbert JC and
Budinger TF. Hypoxia in human gliomas: demonstration by PET with luorine-18-luoromisonidazole. J Nucl Med 1992; 33: 2133-2137.
[61] Spence AM, Muzi M, Swanson KR, O’Sullivan F,
Rockhill JK, Rajendran JG, Adamsen TC, Link
JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL and Krohn KA. Regional hypoxia in
glioblastoma multiforme quantiied with [18F]
luoromisonidazole positron emission tomography before radiotherapy: correlation with
time to progression and survival. Clin Cancer
Res 2008; 14: 2623-2630.
[62] Bentzen L, Keiding S, Nordsmark M, Falborg L,
Hansen SB, Keller J, Nielsen OS and Overgaard
J. Tumour oxygenation assessed by 18F-luoromisonidazole PET and polarographic needle
electrodes in human soft tissue tumours. Radiother Oncol 2003; 67: 339-344.
[63] Rasey JS, Casciari JJ, Hofstrand PD, Muzi M,
Graham MM and Chin LK. Determining hypoxic
fraction in a rat glioma by uptake of radiolabeled luoromisonidazole. Radiat Res 2000;
153: 84-92.
[64] Casciari JJ, Graham MM and Rasey JS. A modeling approach for quantifying tumor hypoxia
with [F-18]luoromisonidazole PET time-activity
data. Med Phys 1995; 22: 1127-1139.
[65] Kelly CJ and Brady M. A model to simulate tumour oxygenation and dynamic [18F]-Fmiso
PET data. Phys Med Biol 2006; 51: 58595873.
[66] Whisenant JG, Peterson TE, Fluckiger JU, Tantawy MN, Ayers GD and Yankeelov TE. Reproducibility of static and dynamic (18)F-FDG,
(18)F-FLT, and (18)F-FMISO MicroPET studies
in a murine model of HER2+ breast cancer.
Mol Imaging Biol 2013; 15: 87-96.
[67] Bejot R, Kersemans V, Kelly C, Carroll L, King
RC, Gouverneur V, Elizarov AM, Ball C, Zhang J,
Miraghaie R, Kolb HC, Smart S and Hill S. Preclinical evaluation of a 3-nitro-1,2,4-triazole
analogue of [18F]FMISO as hypoxia-selective
tracer for PET. Nucl Med Biol 2010; 37: 565575.
[68] Bruehlmeier M, Roelcke U, Schubiger PA and
Ametamey SM. Assessment of hypoxia and
perfusion in human brain tumors using PET
with 18F-luoromisonidazole and 15O-H2O. J
Nucl Med 2004; 45: 1851-1859.
[69] Bruehlmeier M, Kaser-Hotz B, Achermann R,
Bley CR, Wergin M, Schubiger PA and Ametamey SM. Measurement of tumor hypoxia in
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
504
spontaneous canine sarcomas. Vet Radiol Ultrasound 2005; 46: 348-354.
Thorwarth D, Eschmann SM, Paulsen F and Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys
Med Biol 2005; 50: 2209-2224.
Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y,
Rizwan A, O’Donoghue J, Ling CC, Humm JL,
Zanzonico PB and Koutcher JA. Noninvasive
multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of
tumor hypoxia. Neoplasia 2009; 11: 247-259,
242p following 259.
Wang W, Georgi JC, Nehmeh SA, Narayanan M,
Paulus T, Bal M, O’Donoghue J, Zanzonico PB,
Schmidtlein CR, Lee NY and Humm JL. Evaluation of a compartmental model for estimating
tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol 2009; 54: 3083-3099.
Wang W, Lee NY, Georgi JC, Narayanan M, Guillem J, Schoder H and Humm JL. Pharmacokinetic analysis of hypoxia (18)F-luoromisonidazole dynamic PET in head and neck cancer. J
Nucl Med 2010; 51: 37-45.
Takasawa M, Beech JS, Fryer TD, Hong YT,
Hughes JL, Igase K, Jones PS, Smith R, Aigbirhio FI, Menon DK, Clark JC and Baron JC.
Imaging of brain hypoxia in permanent and
temporary middle cerebral artery occlusion in
the rat using 18F-luoromisonidazole and positron emission tomography: a pilot study. J
Cereb Blood Flow Metab 2007; 27: 679-689.
Hong YT, Beech JS, Smith R, Baron JC and Fryer TD. Parametric mapping of [18F]luoromisonidazole positron emission tomography using
basis functions. J Cereb Blood Flow Metab
2011; 31: 648-657.
Nunn A, Linder K and Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med
1995; 22: 265-280.
Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB,
Kim EE and Podoloff DA. Development of F18-labeled luoroerythronitroimidazole as a
PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
van Loon J, Janssen MH, Ollers M, Aerts HJ,
Dubois L, Hochstenbag M, Dingemans AM,
Lalisang R, Brans B, Windhorst B, van Dongen
GA, Kolb H, Zhang J, De Ruysscher D and Lambin P. PET imaging of hypoxia using [18F]HX4:
a phase I trial. Eur J Nucl Med Mol Imaging
2010; 37: 1663-1668.
Vercellino L, Groheux D, Thoury A, Delord M,
Schlageter MH, Delpech Y, Barre E, BaruchHennequin V, Tylski P, Homyrda L, Walker F,
Barranger E and Hindie E. Hypoxia imaging of
uterine cervix carcinoma with (18)F-FETNIM
PET/CT. Clin Nucl Med 2012; 37: 1065-1068.
[80] Lehtio K, Oikonen V, Nyman S, Gronroos T,
Roivainen A, Eskola O and Minn H. Quantifying
tumour hypoxia with luorine-18 luoroerythronitroimidazole ([18F]FETNIM) and PET using
the tumour to plasma ratio. Eur J Nucl Med
Mol Imaging 2003; 30: 101-108.
[81] Lehtio K, Oikonen V, Gronroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grenman R,
Nuutila P and Minn H. Imaging of blood low
and hypoxia in head and neck cancer: initial
evaluation with [(15)O]H(2)O and [(18)F]luoroerythronitroimidazole PET. J Nucl Med 2001;
42: 1643-1652.
[82] Kumar P, Wiebe LI, Asikoglu M, Tandon M and
McEwan AJ. Microwave-assisted (radio)halogenation of nitroimidazole-based hypoxia markers. Appl Radiat Isot 2002; 57: 697-703.
[83] Piert M, Machulla HJ, Picchio M, Reischl G,
Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI and Schwaiger M. Hypoxiaspeciic tumor imaging with 18F-luoroazomycin arabinoside. J Nucl Med 2005; 46:
106-113.
[84] Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H,
Seese A, Dannenberg C, Tannapfel A, Kluge R
and Sabri O. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their
selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol
2003; 30: 317-326.
[85] Postema EJ, McEwan AJ, Riauka TA, Kumar P,
Richmond DA, Abrams DN and Wiebe LI. Initial
results of hypoxia imaging using 1-alpha-D:
-(5-deoxy-5-[18F]-luoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol
Imaging 2009; 36: 1565-1573.
[86] Reischl G, Dorow DS, Cullinane C, Katsiis A,
Roselt P, Binns D and Hicks RJ. Imaging of tumor hypoxia with [124I]IAZA in comparison
with [18F]FMISO and [18F]FAZA--irst small
animal PET results. J Pharm Pharm Sci 2007;
10: 203-211.
[87] Busk M, Munk OL, Jakobsen S, Wang T, Skals
M, Steiniche T, Horsman MR and Overgaard J.
Assessing hypoxia in animal tumor models
based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol 2010; 49: 922-933.
[88] Shi K, Souvatzoglou M, Astner ST, Vaupel P,
Nusslin F, Wilkens JJ and Ziegler SI. Quantitative assessment of hypoxia kinetic models by a
cross-study of dynamic 18F-FAZA and 15OH2O in patients with head and neck tumors. J
Nucl Med 2010; 51: 1386-1394.
[89] Verwer EE, van Velden FH, Bahce I, Yaqub M,
Schuit RC, Windhorst AD, Raijmakers P, Lammertsma AA, Smit EF and Boellaard R. Pharmacokinetic analysis of [18F]FAZA in nonsmall cell lung cancer patients. Eur J Nucl Med
Mol Imaging 2013; 40: 1523-1531.
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
[90] Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H,
Konishi J and Yokoyama A. Copper-62-ATSM: a
new hypoxia imaging agent with high membrane permeability and low redox potential. J
Nucl Med 1997; 38: 1155-1160.
[91] Dehdashti F, Mintun MA, Lewis JS, Bradley J,
Govindan R, Laforest R, Welch MJ and Siegel
BA. In vivo assessment of tumor hypoxia in
lung cancer with 60Cu-ATSM. Eur J Nucl Med
Mol Imaging 2003; 30: 844-850.
[92] Dehdashti F, Grigsby PW, Lewis JS, Laforest R,
Siegel BA and Welch MJ. Assessing tumor
hypoxia in cervical cancer by PET with 60Culabeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-205.
[93] Dietz DW, Dehdashti F, Grigsby PW, Malyapa
RS, Myerson RJ, Picus J, Ritter J, Lewis JS,
Welch MJ and Siegel BA. Tumor hypoxia detected by positron emission tomography with
60Cu-ATSM as a predictor of response and
survival in patients undergoing Neoadjuvant
chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51: 16411648.
[94] Yuan H, Schroeder T, Bowsher JE, Hedlund LW,
Wong T and Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging
agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-998.
[95] O’Donoghue JA, Zanzonico P, Pugachev A, Wen
B, Smith-Jones P, Cai S, Burnazi E, Finn RD,
Burgman P, Ruan S, Lewis JS, Welch MJ, Ling
CC and Humm JL. Assessment of regional tumor hypoxia using 18F-luoromisonidazole and
64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2
probe measurement, autoradiography, and
luorescent microscopy in the R3327-AT and
FaDu rat tumor models. Int J Radiat Oncol Biol
Phys 2005; 61: 1493-1502.
[96] Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y and Welch MJ. Evaluation of 64CuATSM in vitro and in vivo in a hypoxic tumor
model. J Nucl Med 1999; 40: 177-183.
[97] Lewis JS, Herrero P, Sharp TL, Engelbach JA,
Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ
and Welch MJ. Delineation of hypoxia in canine
myocardium using PET and copper(II)-diacetylbis(N(4)-methylthiosemicarbazone). J Nucl
Med 2002; 43: 1557-1569.
[98] Dearling JL and Packard AB. Some thoughts on
the mechanism of cellular trapping of Cu(II)ATSM. Nucl Med Biol 2010; 37: 237-243.
[99] Burgman P, O’Donoghue JA, Lewis JS, Welch
MJ, Humm JL and Ling CC. Cell line-dependent
differences in uptake and retention of the hypoxia-selective nuclear imaging agent CuATSM. Nucl Med Biol 2005; 32: 623-630.
505
[100] Holland JP, Giansiracusa JH, Bell SG, Wong LL
and Dilworth JR. In vitro kinetic studies on the
mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys
Med Biol 2009; 54: 2103-2119.
[101] Bowen SR, van der Kogel AJ, Nordsmark M,
Bentzen SM and Jeraj R. Characterization of
positron emission tomography hypoxia tracer
uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol 2011; 38:
771-780.
[102] Dalah E, Bradley D and Nisbet A. Simulation of
tissue activity curves of (64)Cu-ATSM for subtarget volume delineation in radiotherapy.
Phys Med Biol 2010; 55: 681-694.
[103] McCall KC, Humm JL, Bartlett R, Reese M and
Carlin S. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu
xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol
Biol Phys 2012; 84: e393-399.
[104] Rust TC and Kadrmas DJ. Rapid dual-tracer
PTSM+ATSM PET imaging of tumour blood low
and hypoxia: a simulation study. Phys Med Biol
2006; 51: 61-75.
[105] Black NF, McJames S, Rust TC and Kadrmas
DJ. Evaluation of rapid dual-tracer (62)CuPTSM + (62)Cu-ATSM PET in dogs with spontaneously occurring tumors. Phys Med Biol
2008; 53: 217-232.
[106] Black NF, McJames S and Kadrmas DJ. Rapid
Multi-Tracer PET Tumor Imaging With F-FDG
and Secondary Shorter-Lived Tracers. IEEE
Trans Nucl Sci 2009; 56: 2750-2758.
[107] Ikoma Y, Watabe H, Shidahara M, Naganawa M
and Kimura Y. PET kinetic analysis: error consideration of quantitative analysis in dynamic
studies. Ann Nucl Med 2008; 22: 1-11.
[108] Wu FX and Mu L. Parameter estimation in rational models of molecular biological systems.
Conf Proc IEEE Eng Med Biol Soc 2009; 2009:
3263-3266.
[109] Luenberger D. Optimization by vector space
methods. New York: Wiley; 1969.
[110] Marquardt D. An algorithm for least squares
estimation of nonlinear parameters. SIAM J
Soc Ind Appl Math 1963; 11: 431-441.
[111] Dai X, Chen Z and Tian J. Performance evaluation of kinetic parameter estimation methods
in dynamic FDG-PET studies. Nucl Med Commun 2011; 32: 4-16.
[112] Croteau E, Lavallee E, Labbe SM, Hubert L,
Pifferi F, Rousseau JA, Cunnane SC, Carpentier
AC, Lecomte R and Benard F. Image-derived
input function in dynamic human PET/CT:
methodology and validation with 11C-acetate
and 18F-luorothioheptadecanoic acid in muscle and 18F-luorodeoxyglucose in brain. Eur J
Nucl Med Mol Imaging 2010; 37: 1539-1550.
Am J Nucl Med Mol Imaging 2014;4(5):490-506
Kinetic modeling in hypoxia PET imaging
[113] Fang YH and Muzic RF Jr. Spillover and partialvolume correction for image-derived input
functions for small-animal 18F-FDG PET studies. J Nucl Med 2008; 49: 606-614.
[114] Laforest R, Sharp TL, Engelbach JA, Fettig NM,
Herrero P, Kim J, Lewis JS, Rowland DJ, Tai YC
and Welch MJ. Measurement of input functions in rodents: challenges and solutions.
Nucl Med Biol 2005; 32: 679-685.
[115] Zanotti-Fregonara P, Chen K, Liow JS, Fujita M
and Innis RB. Image-derived input function for
brain PET studies: many challenges and few
opportunities. J Cereb Blood Flow Metab 2011;
31: 1986-1998.
[116] Hueting R, Kersemans V, Cornelissen B,
Tredwell M, Hussien K, Christlieb M, Gee AD,
Passchier J, Smart SC, Dilworth JR, Gouverneur V and Muschel RJ. A comparison of the
behavior of (64)Cu-acetate and (64)Cu-ATSM
in vitro and in vivo. J Nucl Med 2014; 55: 128134.
506
[117] Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, Simpson E, Parkey RW, Sun X
and Oz OK. Retention of the radiotracers
64Cu-ATSM and 64Cu-PTSM in human and
murine tumors is inluenced by MDR1 protein
expression. J Nucl Med 2009; 50: 1332-1339.
[118] El Fakhri G, Sitek A, Guerin B, Kijewski MF, Di
Carli MF and Moore SC. Quantitative dynamic
cardiac 82Rb PET using generalized factor and
compartment analyses. J Nucl Med 2005; 46:
1264-1271.
Am J Nucl Med Mol Imaging 2014;4(5):490-506